Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410923 | 1.00 | KMT2A (0.45) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL12555211 | 0.95 | KMT2A (0.47) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL4395836 | 0.92 | KMT2A (0.45) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL9706968 | 0.92 | KMT2A (0.45) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL12873284 | 0.91 | LMNA (0.46) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL1623874 | 0.91 | KMT2A (0.44) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL12588064 | 0.89 | KMT2A (0.42) | KMT2AMEN1EPHX2MDM2CASP3 | |
| SCHEMBL1745934 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL16316701 | 0.89 | KMT2A (0.42) | KMT2AMEN1MDM2CASP3FABP5 | |
| SCHEMBL3367289 | 0.89 | KMT2A (0.45) | KMT2AMEN1MDM2CASP3FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110114075-A | Disulfide-containing cell penetrating peptides and methods of making and using the same | 俄亥俄州国家创新基金会 | 2019-08-09 | — | — | CN | disclosed |
| CN-108026153-A | The alternatively new exendin-4 derivative of the dual GLP-1/ glucagon receptors activator of property peptide | 赛诺菲 | 2018-05-11 | — | — | CN | disclosed |
| CN-107636007-A | Beta hairpin peptide mimics | 波利弗尔股份公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-104220452-B | For the APELIN analogies for the synthesis for treating heart failure | 诺华股份有限公司 | 2018-01-26 | — | — | CN | disclosed |
| CN-107406490-A | Synthesis APELIN fatty acid conjugates with improved half-life period | 诺华股份有限公司 | 2017-11-28 | — | — | CN | disclosed |
| CN-107073130-A | Fatty acids and their use in conjugation with biomolecules | 诺华股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-106573955-A | Site-specific protein modification | 诺华股份有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-20150299261-A1 | EPTIFIBATIDE PREPARATION METHOD | CHENGDU SHENGNUO BIO TEC CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| CN-104220452-A | Synthetic APELIN mimetics for treatment of heart failure | NOVARTIS AG | 2014-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299261-A1 | EPTIFIBATIDE PREPARATION METHOD | RXFP1, OGFR, RXFP3 | KMT2A 3326/4885MEN1 4111/4885EPHX2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.